N6-Propyl-4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine Hydrochloride (1:1)

In pharmaceutical manufacturing, N6-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrochloride (1:1) is supplied as a crystalline, anhydrous monohydrochloride salt with a molecular formula of C₁₀H₁₈ClN₃S and a relative molecular mass of 247.79 g/mol. The compound is the immediate precursor to the non-ergoline dopamine agonist pramipexole dihydrochloride monohydrate and shares the identical (S)-enantiomeric configuration required for D₂/D₃ receptor affinity. Bulk material typically exhibits a purity of ≥ 99.0% (by HPLC, area normalization) and is characterized by a specific optical rotation [α]²⁰_D of approximately −67° to −69° (c=1, methanol), distinguishing it from the racemic mixture or the pharmacologically inert (R)-isomer.

What Conditions Trigger Disproportionation of the Monohydrochloride Salt?

The 1:1 stoichiometry defines a critical physicochemical boundary. Unlike the dihydrochloride monohydrate form listed in USP 43-NF 38, the monohydrochloride lacks a second chloride counterion and the water of crystallization that stabilizes the crystal lattice of the final drug substance. This renders the 1:1 salt susceptible to humidify-induced disproportionation at relative humidity levels exceeding 40% RH at 25°C. Dynamic vapor sorption (DVS) analysis on a Surface Measurement Systems DVS Intrinsic reveals a step-change mass uptake of 2.8–3.2% w/w between 40% and 60% RH, corresponding to the uptake of approximately one equivalent of water and partial conversion to the free base hydrate. Processing environments must therefore maintain a dew point below −5°C, and fluid-bed drying in the subsequent synthetic step is typically conducted with inlet air at ≤ 15% RH to preserve solid-state integrity.

Impurity Fingerprinting and the Tetrahydrobenzothiazole Scaffold

The chemical route to N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine hydrochloride (1:1) proceeds via reductive amination of the 6-keto intermediate with n-propylamine, often using sodium triacetoxyborohydride in 1,2-dichloroethane. This pathway generates a characteristic impurity profile that differs markedly from alternative synthetic strategies. A typical batch analyzed using a Waters XBridge C₁₈ column (150 x 4.6 mm, 3.5 μm) with UV detection at 262 nm shows the following resolution-critical pairs:

• Des-propyl impurity (4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine): relative retention time (RRT) 0.64, limit ≤ 0.10%
• (R)-enantiomer (ent-pramipexole): RRT 1.12 on a Chiralpak IA-3 column (250 x 4.6 mm, 3 μm), limit ≤ 0.15%
• N6-ethyl analog: RRT 0.89, limit ≤ 0.10%
• Dimeric impurity (bis-tetrahydrobenzothiazole propylamine): RRT 2.41, limit ≤ 0.10%

Total related substances are controlled to ≤ 0.5% in accordance with ICH Q3A(R2) thresholds for drug substances with a maximum daily dose of 1.5 mg (as pramipexole base). The absence of the 7-propylamino regioisomer, which co-elutes with the active peak under conventional reversed-phase conditions, is confirmed using a phenyl-hexyl stationary phase with a mobile phase containing 25 mM ammonium bicarbonate at pH 8.9.

Without a formal section header, the handling characteristics of the bulk intermediate demand attention because the physical form delivered by manufacturers directly impacts downstream formulation uniformity. The primary particle size distribution, measured by laser diffraction using a Malvern Mastersizer 3000 with an Aero S dry dispersion unit at 2.0 bar, typically shows a D₁₀ of 4–8 μm, D₅₀ of 18–30 μm, and D₉₀ of 50–80 μm. Material with a D₉₀ exceeding 100 μm exhibits incomplete dissolution during the salt-exchange step in ethanolic HCl, leading to lower yields of the dihydrochloride monohydrate and elevated residual monohydrochloride in the final API. Milling through a conical screen mill with a 0.5 mm rasping screen at 3,000 rpm reduces oversized particles while generating minimal fines (< 4% below 5 μm), preserving flowability for solid-transfer operations in isolator-contained lines.

Distinguishing the Monohydrochloride from Ergot-Derived Agonists

A comparison with older dopamine agonists underscores the toxicological and regulatory distance that the tetrahydrobenzothiazole scaffold creates. Ergot-based drugs such as pergolide and cabergoline are associated with dose-dependent fibrotic valvulopathy mediated by 5-HT_2B receptor agonism. The N6-propyl monohydrochloride, as the penultimate intermediate to a non-ergot agent, carries no detectable ergoline alkaloid residues when tested per Ph. Eur. 5.4 (limit of aflatoxin-like structures using post-column photochemical derivatization). Furthermore, the compound’s selectivity ratio—D₃ receptor K_i over D₂ receptor K_i—approximates 0.12 for the active (S)-form, a profile first established in the intermediate stage and preserved through final salt crystallization. This contrasts sharply with ropinirole hydrochloride, which exhibits a D₃/D₂ K_i ratio closer to 0.38 and lacks the 2,6-diaminothiazole motif that enables additional hydrogen-bonding contacts with serine residues in transmembrane domain 5.

Structural and Pharmacological Comparison: Non-Ergoline Dopamine Agonist Intermediates

Parameter	N6-Propyl-4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine HCl (1:1)	Ropinirole HCl	Rotigotine (Free Base Intermediate)
Core heterocycle	2,6-diamino-4,5,6,7-tetrahydrobenzothiazole	4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one	5,6,7,8-tetrahydro-6-(2-thienyl)-4-naphthalenol
Receptor binding target	D3 > D2 (Ki ~ 0.5 nM at D3)	D2 > D3 (Ki ~ 2.2 nM at D2)	D3 < D2 (Ki ~ 0.4 nM at D3)
Chiral center(s)	1	0	1
Enantiomeric requirement	(S)-configured; R-isomer is a mutagenic impurity controlled to ≤ 0.15%	Not applicable	(S)-configured; R-isomer is inactive
Typical salt form	Monohydrochloride anhydrous (this intermediate)	Hydrochloride monohydrate	Transdermal base; no salt formed
Hygroscopicity (ms at 60% RH)	+2.9% w/w (disproportionation observed)	+0.8% w/w (monohydrate stable)	+0.2% w/w
Critical process impurity	Des-propyl diamine (RRT 0.64)	4-des-alkyl impurity	N-oxide photodegradant

Why Pre-formulation Screening of the 1:1 Salt Includes Forced Degradation at Elevated pO₂

The 2,6-diamine substitution on the tetrahydrobenzothiazole core creates an electron-rich system susceptible to autoxidation when the monohydrochloride is stored under ambient oxygen partial pressure. Forced degradation studies conducted per ICH Q1A(R2) conditions expose the salt to 80°C at 90% relative oxygen saturation for 14 days, revealing a primary degradation pathway to the N²-oxide metabolite via a radical-mediated mechanism. This degradant, measured by UPLC-MS/MS (Waters ACQUITY I-Class with QDa detector), increases from < 0.05% to 0.28–0.33% within the exposure window. Consequently, nitrogen-blanketed packaging (residual oxygen < 3.0% in headspace) and the inclusion of a desiccant canister containing molecular sieve 4A are specified for bulk shipments exceeding 5 kg. The difference here from pramipexole dihydrochloride monohydrate is substantial—the monohydrate salt exhibits a solution-mediated autoxidation that is 4-fold slower, attributed to the hydrogen-bonded water molecule reducing electrophilicity at the thiazole nitrogen.

The reactivity profile also dictates incompatibility with strong oxidizing agents and bases. Contact with potassium carbonate or sodium hydroxide in solution immediately liberates the free base, which has a pK_a of approximately 9.1 for the secondary amine and 6.0 for the aromatic amine, and undergoes rapid phase separation as a waxy semi-solid. In continuous manufacturing platforms employing tubular reactors for the final dihydrochloride formation, a static mixer upstream of the HCl addition point must maintain a Reynolds number of ≥ 2,100 to prevent localized free-base precipitation that fouls the reactor walls. Published data for this specific configuration in open literature is limited, but internal technical reports from kilo-lab operations recommend a solvent system of methanol : tetrahydrofuran (1:3 v/v) to dissolve the monohydrochloride before salt exchange, reducing viscosity from 12 cP to 4 cP at 20°C.

When Residual Solvent Limits Set the Specification Envelope

The choice of n-propylamine and the reductive amination solvent (commonly 1,2-dichloroethane) introduces Class 1 and Class 2 residual solvents that must be controlled below ICH Q3C(R8) Option 2 concentration limits. The monohydrochloride specification includes:

• 1,2-Dichloroethane: ≤ 5 ppm (Class 1)
• Methanol: ≤ 3,000 ppm (Class 2)
• Acetonitrile: ≤ 410 ppm (Class 2)
• Triethylamine: ≤ 320 ppm (Class 3, but monitored due to odor threshold)

Headspace GC-FID analysis on an Agilent 7890B with a DB-624 column (30 m × 0.32 mm, 1.8 µm film) using a split ratio of 10:1 achieves a limit of quantitation of 1 ppm for 1,2-dichloroethane. Batches that fail the 5 ppm threshold require a reslurry in water followed by vacuum tray drying at 45°C and ≤ 10 mbar for 16 hours, a cycle that routinely reduces residual solvent by 60–70% without inducing salt disproportionation. Key physical constants that serve as release criteria include melting point (onset 215–220°C, determined by differential scanning calorimetry at 10°C/min under 50 mL/min nitrogen purge), chloride content by potentiometric titration (13.8–14.5% w/w, theoretical 14.35%), and water content by Karl Fischer coulometry (≤ 1.0% w/w, reflecting the anhydrous nature). When compared to the free base—which melts at 118–122°C and exhibits a water solubility less than 0.5 mg/mL—the 1:1 hydrochloride demonstrates aqueous solubility in excess of 25 mg/mL at 25°C, enabling direct use in aqueous-phase biocatalysis for chemoenzymatic route scouting.

Batch Release Specification Summary (Representative)

Test Parameter	Acceptance Criteria	Analytical Procedure Reference
Appearance	White to off-white crystalline powder	Visual, Ph. Eur. 2.2.23
Identification (IR)	Conforms to reference spectrum; characteristic N-H stretch at 3350 cm⁻¹	Ph. Eur. 2.2.24, KBr disc
Chiral purity	(R)-enantiomer ≤ 0.15%	HPLC, Chiralpak IA-3, n-hexane:ethanol:DEA (85:15:0.1)
Assay (anhydrous basis)	98.0–102.0%	HPLC, C18, phosphate buffer pH 3.0:MeOH (80:20)
Total related substances	≤ 0.5%	HPLC, gradient as per in-house method PRM-0012
Water (KF)	≤ 1.0%	Ph. Eur. 2.5.12, coulometric
Residual solvents	1,2-DCE ≤ 5 ppm; MeOH ≤ 3,000 ppm; Et3N ≤ 320 ppm	GC-HS, as per in-house method PRM-0083
Heavy metals	≤ 10 ppm	Ph. Eur. 2.4.8, Method C
Chloride content	13.8–14.5% w/w	Argentometric titration, USP <541>

What Distinguishes the 1:1 Hydrochloride in Multi-Kilogram Aseptic Campaigns?

Execution of a final cGMP alkylation step from this intermediate imposes sterility requirements that dictate the physical form’s bioburden envelope. The monohydrochloride intermediate, as the last isolated solid before the final salt metathesis, must meet a microbial limit of < 10 CFU/g with absence of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus per 1 g sample (Ph. Eur. 5.1.4). Terminal sterilization by gamma irradiation is contraindicated: dose mapping at 15 kGy reveals a 0.3–0.5% increase in the (R)-enantiomer content due to free-radical inversion at the chiral center, exceeding the 0.15% threshold. Instead, the material is crystallized from sterile-filtered ethanol under closed isolator conditions with continuous viable particle monitoring per ISO 14644-1 Class 5. This contrasts with the dihydrochloride API, which can be sterile-filtered in aqueous solution, providing a flexibility that the 1:1 salt does not share due to rapid precipitation of the free base at neutral pH. Process analytical technology (PAT) integration for real-time release of the intermediate employs Raman spectroscopy with a Kaiser RXN2 probe, monitoring the 680 cm⁻¹ C-S stretching band and the 1620 cm⁻¹ C=N ring vibration. A partial least-squares model correlated to gravimetric water content and (R)-enantiomer concentration enables a batch disposition decision within 4 minutes after filtration, bypassing off-line KF and chiral HPLC delays that historically consumed 6–8 hours. The measurement uncertainty of ±0.04% w/w for water at the 0.5% level meets the regulatory target for use as a surrogate method. Thermal hazard screening via accelerating rate calorimetry (ARC) applied to the neat monohydrochloride in a Netzsch ARC 254 at 0.5°C min⁻¹ from 50°C to 350°C reveals an onset of self-heating at 190°C and a maximum self-heat rate of 1.8°C min⁻¹ at 240°C, placing the material below the critical energy release threshold for manufacturing safety. However, when mixed with 1,2-dichloroethane (simulating a wet cake condition), the onset temperature drops to 135°C, necessitating a drying temperature limit of 60°C with forced convection and a safety margin of 50°C below adiabatic onset. This thermochemical profile differs from the dihydrochloride monohydrate, which exhibits endothermic dehydration near 95°C that partially self-quenches thermal runaway. The single anhydrous polymorph observed (Form I) has been indexed with a monoclinic P2₁ space group and unit cell parameters a = 10.518 Å, b = 7.236 Å, c = 15.041 Å, β = 98.23°, Z = 2. There is no evidence of a polymorphic transition before melting, confirmed by variable-temperature XRPD from 25°C to 200°C in 10°C increments. This monomorphism removes the need for form-specific specifications, differentiating the intermediate from drugs where salt-to-base transitions or hydrate formation complicate equivalence. Consequently, bioequivalence risk for the subsequent dihydrochloride monohydrate product is not introduced by the intermediate’s solid form variability. That stability of form constitutes a critical difference from the dihydrochloride salt, which is routinely manufactured as a monohydrate and must be monitored for dehydration-induced crystallinity loss at humidities below 15% RH.